弥漫性大B细胞淋巴瘤治疗进展

Advances in the Treatment of Diffuse Large B-Cell Lymphoma

弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma, DLBCL)是非霍奇金淋巴瘤(non-Hodgkin’s lymphoma, NHL)最常见的亚型,包括一组形态学、遗传学和临床上不同的异质性疾病。据估计,全球每年有150,000例新发病例的大B细胞淋巴瘤,患者通常表现为进行性淋巴结肿大、结外病变或两者兼而有之,需要治疗。在过去的二十年里,人们对弥漫性大B细胞淋巴瘤的流行病学、组织学、免疫表型、遗传学特征、临床表现、化疗疗效及预后和生物异质性有了更深入的了解,从而完善了疾病分类并开发了新的治疗方法。在此,我们回顾了DLBCL治疗手段的最新进展,并展望与讨论了DLBCL患者未来的治疗前景。

Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma (NHL) and comprises a heterogeneous group of morphologically, genetically, and clinically distinct diseases. An estimated 150,000 new cases of large B-cell lymphoma occur globally each year, and patients usually present with progressive lymph node enlargement, extranodal lesions, or both, requiring treatment. Over the past two decades, a better understanding of the epidemiology, his-tology, immunophenotype, genetic features, clinical presentation, chemotherapy efficacy and prog-nosis, and biological heterogeneity of diffuse large B-cell lymphomas has led to refinement of dis-ease classifications and development of new therapeutic approaches. Here, we review the recent advances in the treatment of DLBCL and look forward to and discuss the future prospects for the treatment of patients with DLBCL.